ABT vs LEXXW · P/E 25, rev $44.33B vs rev $705.9K
Abbott Laboratories (ABT) versus Lexaria Bioscience Corp (LEXXW) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Lexaria Bioscience Corp (LEXXW) common stock listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported LEXXW revenue for 2025-08-31 was $705.9K. Net income was -$11.9M. Revenue was up 52.0% from 2024-08-31 to 2025-08-31. LEXXW currently screens at market cap $33.8M.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. LEXXW currently screens at market cap $33.8M.
Not investment advice. Open the ABT and LEXXW stock pages for the full models.
Not investment advice.